Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

9 Mar 2012 17:07

RNS Number : 1034Z
Vernalis PLC
09 March 2012
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Vernalis plc

 

 

2 Reason for the notification (please tick the appropriate box or boxes):

 

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

Change in ISC

X

 

3. Full name of person(s) subject to the notification obligation:

 

Ignis Investment Services Limited

4. Full name of shareholder(s) (if different from 3.):

 

5. Date of the transaction and date on which the threshold is crossed or reached:

 

5 March, 2012

6. Date on which issuer notified:

 

6 March, 2012

7. Threshold(s) that is/are crossed or reached:

 

3%

 

8. Notified details:

A: Voting rights attached to shares

 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

Ordinary 1p Shares

3,580,831

0.81%

 GB00B3Y5L754

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Expirationdate

Exercise/ConversionPeriod

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Exerciseprice

Expirationdate

Exercise/Conversionperiod

Number of votingrights instrumentrefers to

% of voting rights

 

Nominal

Delta

 

 

Total (A+B+C)

 

Number of voting rights

Percentage of voting rights

3,580,831

0.81%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

Vidacos Nominees Ltd (3,580,831 - 0.81%)

 

Phoenix Group Holdings

Impala Holdings Limited

Ignis Asset Management Ltd

Ignis Investment Services Ltd (indirect)

 

 

Proxy Voting:

 

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

 

13. Additional information:

 

Notice of change in this major interest was sent on 06/03/2012 to an incorrect e-mail address at the issuer as was, on 16/02/2012, an earlier notice of change informing the issuer of a 3,025,000 interest (3.04%). The issuer has informed the notifier of the correct e-mail address to send any such notice in future.

14. Contact name:

 

Kevin Kissane

General Counsel & Company Secretary

15. Contact telephone number:

 

0118 989 9334

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLSSSFWUFESESD
Date   Source Headline
6th Mar 20125:29 pmRNSHolding(s) in Company
5th Mar 20125:39 pmRNSHolding(s) in Company
2nd Mar 20129:22 amRNSVoting Rights and Capital
28th Feb 201212:28 pmRNSResult of General Meeting
28th Feb 20127:00 amRNSResult of Open Offer
10th Feb 20124:53 pmRNSPublication of Combined Circular and Prospectus
10th Feb 20127:00 amRNSLicence Agreemt &Firm Placing &Placing &Open Offer
10th Feb 20127:00 amRNSVernalis and Tris Pharma Announce Collaboration
17th Jan 20127:00 amRNSVernalis & Servier Sign 3rd Oncology Collaboration
4th Jan 20127:00 amRNSVernalis enters collaboration with Genentech
19th Dec 20117:00 amRNSSecond Research Milestone Achieved
12th Dec 20117:00 amRNSVernalis Earns Final Milestone Payment from Ipsen
16th Nov 20117:00 amRNSInterim Management Statement
7th Nov 201111:43 amRNSHolding(s) in Company
3rd Oct 20117:00 amRNSMilestone Achieved and Collaboration Extended
28th Sep 20117:00 amRNSPositive Results for V158866 in Phase I Study
21st Sep 20117:00 amRNSResearch Milestone Achieved
8th Sep 20114:40 pmRNSSecond Price Monitoring Extn
8th Sep 20114:35 pmRNSPrice Monitoring Extension
24th Aug 20117:00 amRNSVernalis Initiates Phase I Trial of V81444
17th Aug 20115:16 pmRNSReplacement - Director/PDMR Shareholding
17th Aug 20114:35 pmRNSDirector/PDMR Shareholding
12th Aug 201110:00 amRNSDirector/PDMR Shareholding
5th Aug 201111:59 amRNSHolding(s) in Company
3rd Aug 20117:00 amRNSInterim results for six months ended 30 June 2011
3rd Aug 20117:00 amRNSAppointment of Non-Executive Director
2nd Aug 201111:30 amRNSVernalis Appoints Corporate Broker
22nd Jul 20117:00 amRNSNotice of Results for Six Months Ended 30 June '11
20th Jul 20117:00 amRNSAUY922 Update
5th Jul 20114:40 pmRNSSecond Price Monitoring Extn
5th Jul 20114:35 pmRNSPrice Monitoring Extension
15th Jun 201111:30 amRNSResult of AGM
8th Jun 20114:20 pmRNSHolding(s) in Company
26th May 20114:41 pmRNSSecond Price Monitoring Extn
26th May 20114:35 pmRNSPrice Monitoring Extension
26th May 20114:17 pmRNSListing Application, Voting Rights, Share Capital
23rd May 20114:58 pmRNSHolding(s) in Company
19th May 20114:40 pmRNSSecond Price Monitoring Extn
19th May 20114:35 pmRNSPrice Monitoring Extension
13th May 20117:00 amRNSTosedostat data to be presented at ASCO
11th May 20117:00 amRNSInterim Management Statement
6th May 20117:01 amRNSDirector/PDMR Shareholding
6th May 20117:00 amRNSDirector/PDMR Shareholding
4th May 20117:01 amRNSAnnual Information Update
4th May 20117:00 amRNSNotice of AGM
20th Apr 201111:57 amRNSHolding(s) in Company
12th Apr 20114:40 pmRNSSecond Price Monitoring Extn
12th Apr 20114:35 pmRNSPrice Monitoring Extension
12th Apr 20117:00 amRNSResults for the year ended 31 December 2010
12th Apr 20117:00 amRNSVernalis Regains A2A Receptor Antagonist Programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.